Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027742 | 1.00 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2NPSR1 | |
| SCHEMBL3856318 | 0.86 | DGAT1 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2NPSR1 | |
| SCHEMBL14601099 | 0.84 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL7597173 | 0.84 | MGAM (0.35) | SMYD2CYP3A4HTTSMN1; SMN2NPSR1 | |
| SCHEMBL535138 | 0.83 | KDM4E (0.36) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL18748478 | 0.83 | NR1H2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17839109 | 0.83 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17839089 | 0.83 | NR1H2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| Octanoic Acid SCHEMBL25178883 | 0.83 | PPARA (0.41) | — | |
| SCHEMBL535191 | 0.82 | KDM4E (0.35) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545931-B2 | Method for transfection into cardiomyocytes using cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12479791-B2 | Cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250197343-A1 | CATIONIC LIPID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-3835287-B1 | CATIONIC LIPID | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-02 | — | — | EP | disclosed |
| EP-4431489-A1 | CATIONIC LIPID | Takeda Pharmaceutical Company Limited (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-11993570-B2 | Cationic lipids | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3733641-B1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-111511713-B | Cationic lipid | 武田药品工业株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-117304048-A | Cationic lipid | 武田药品工业株式会社 | 2023-12-29 | — | — | CN | disclosed |
| US-7772278-B2 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7449595-B2 | for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions | NITROMED, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | GIFU UNIVERSITY (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1798225-A1 | NUCLEOSIDE ANALOGUES OR SALTS THEREOF | Gifu University (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20070112067-A1 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-7176238-B1 | Nitrostated and nitrosylated prostaglandins, compositions and methods of use | NITROMED INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070021380-A1 | Novel drug delivery compositions | WIEBE LEONARD | 2007-01-25 | — | — | US | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993570-B2 | Cationic lipids | ELOVL5, LPCAT3, ELOVL3 | SMYD2 1180/4885CYP3A4 4070/4885HTT 2866/4885 |
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | PTGIS, PGF, PTGS1 | SMYD2 1405/4885CYP3A4 651/4885HTT 2506/4885 |
| US-20070249548-A1 | Nucleoside Analog or Salts of the Same | NSUN2, RNMT, RNGTT | SMYD2 762/4885CYP3A4 4614/4885HTT 3617/4885 |
| US-20250197343-A1 | CATIONIC LIPID | NR1H3, NR1H2, NR1H4 | SMYD2 1648/4885CYP3A4 2514/4885HTT 2842/4885 |
| US-12479791-B2 | Cationic lipid | LIPC, NPC1, LPCAT1 | SMYD2 1211/4885CYP3A4 4326/4885HTT 1530/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | SMYD2 672/4885CYP3A4 504/4885HTT 1567/4885 |
| US-20070021380-A1 | Novel drug delivery compositions | NME4, NUDT1, NT5C2 | SMYD2 3403/4885CYP3A4 4610/4885HTT 206/4885 |
| US-12545931-B2 | Method for transfection into cardiomyocytes using cationic lipid | TNNT2, TNNC1, TNNI3 | SMYD2 599/4885CYP3A4 4878/4885HTT 1322/4885 |
| US-20070112067-A1 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | PTGIS, PGF, PTGS1 | SMYD2 1405/4885CYP3A4 651/4885HTT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.